The earnings call highlighted strong growth in QUVIVIQ sales, significant improvements in financial metrics, and promising pipeline developments. However, challenges remain with flat U.S. sales and uncertainties in regulatory processes. Overall, positive developments and strategic advancements contribute to a cautiously optimistic outlook.

Company Guidance

In the Idorsia Half Year 2025 Financial Results Webcast and Conference Call, the company provided an optimistic outlook for its future performance. The guidance reiterated the goal of achieving commercial profitability in 2026 and overall profitability by the end of 2027. Key metrics highlighted include a significant growth in QUVIVIQ net sales, which more than doubled from CHF 23 million to CHF 56 million in the first half of 2025. The non-GAAP operating results improved dramatically, from a loss of CHF 170 million to a loss of CHF 15 million. The company's cash runway was extended to the end of 2026, securing further financial stability. Additionally, Idorsia updated its guidance for the partner-led business due to higher milestone payments, leading to an overall non-GAAP EBIT loss of CHF 100 million and a U.S. GAAP EBIT loss of CHF 55 million for 2025. These developments position Idorsia on a solid path to achieving its strategic and financial objectives.

QUVIVIQ Sales Surge

QUVIVIQ net sales in H1 2025 more than doubled compared to last year, rising from CHF 23 million to CHF 56 million, showcasing strong commercial traction and growing demand.

Significant Operating Improvement

Improvement in non-GAAP operating results from negative CHF 170 million to negative CHF 15 million, driven by financial discipline and increased sales.

Strategic Partnerships and Approvals

Secured new partnerships and approvals, including QUVIVIQ's approval in China with Simcere, contributing to the extension of Idorsia's cash runway to the end of 2026.

Positive Financial Metrics

Net revenue of CHF 130 million includes CHF 58 million from total QUVIVIQ product sales, a significant increase compared to CHF 24 million in H1 2024.

Pipeline Advancements

Advancements in the pipeline with new data for lucerastat supporting further Phase III investigation, and Phase I study for C. diff vaccine showing positive results.

Idorsia Ltd (CH:IDIA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:IDIA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.19 / -	-0.462	―	―	―
Jul 30, 2025	2025 (Q2)	-0.20 / -0.01	-0.54	98.15% (+0.53)	―	―
Apr 30, 2025	2025 (Q1)	- / -0.61	0.13	-569.23% (-0.74)	―	―
Mar 04, 2025	2024 (Q4)	-0.56 / -0.39	-0.675	42.22% (+0.29)	―	―
Oct 29, 2024	2024 (Q3)	-0.53 / -0.46	0.96	-148.13% (-1.42)	―	―
Jul 25, 2024	2024 (Q2)	-0.36 / -0.54	-1.08	50.00% (+0.54)	―	―
May 21, 2024	2024 (Q1)	0.17 / 0.13	-1.19	110.92% (+1.32)	―	―
Apr 25, 2024	2023 (Q4)	- / -	-1.19	―	―	―
Oct 24, 2023	2023 (Q3)	-0.97 / 0.96	-1.14	184.21% (+2.10)	―	―
Jul 25, 2023	2023 (Q2)	-0.95 / -1.08	-1.25	13.60% (+0.17)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:IDIA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	CHF2.71	CHF3.34	+23.25%
Apr 30, 2025	CHF1.18	CHF1.29	+9.32%
Mar 04, 2025	CHF1.24	CHF1.18	-4.84%
Oct 29, 2024	CHF1.18	CHF1.18	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Idorsia Ltd (CH:IDIA) report earnings?

Idorsia Ltd (CH:IDIA) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Idorsia Ltd (CH:IDIA) earnings time?

Idorsia Ltd (CH:IDIA) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Idorsia Ltd stock?

The P/E ratio of Idorsia Ltd is N/A.

What is CH:IDIA EPS forecast?

CH:IDIA EPS forecast for the fiscal quarter 2025 (Q3) is -0.19.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing